Skip to main content

Table 2 First line trials of 2 nd generation TKI in EGFR mutated patients

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

 

N

OR%

mPFS (mo)

mOS (mo)

Dacomitinib

    

Phase II trial30

92

74

17

NR

Afatinib

    

LUX LUNG II trial 34

    

All EGFR mutations

129

61

10.1

24.8

Exon 19–21 mutations

106

66

13.7

38.7

LUX LUNG III trial 35

    

All EGFR mutations

    

Afatinib

230

56

11.1

NR

Cis/Gem

115

23

6.9

NR

Exon 19–21 mutations

    

Afatinib

204

-

13.6

NR

Cis/Gem

104

-

6.9

NR

LUX LUNG VI trial 39

    

All EGFR mutations

    

Afatinib

242

66.9

11.1

 

Cis/Gem

122

23

5.6

 

XL647

    

Phase II trial53

    

All EGFR mutations

41

20

5.3

19

Exon 19–21 mutations

14

57

9.3

NR